dc.contributor.author | Karadag, Omer | |
dc.contributor.author | Duran, Emine | |
dc.date.accessioned | 2021-03-18T07:45:24Z | |
dc.date.available | 2021-03-18T07:45:24Z | |
dc.date.issued | 2020-06-20 | |
dc.identifier.citation | Karadag, O., Duran, E. Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions. Intern Emerg Med 16, 33–35 (2021). https://doi.org/10.1007/s11739-020-02481-2 | tr_TR |
dc.identifier.uri | https://doi.org/10.1007/s11739-020-02481-2 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s11739-020-02481-2 | |
dc.identifier.uri | http://hdl.handle.net/11655/23575 | |
dc.description.abstract | Cryoglobulinemic vasculitis (CryoVas) is a systemic
immune-complex vasculitis which can be a life-threatening
condition. In their article recently published by Internal and
Emergency Medicine, Vacchi C et al. reported the safety
and effectiveness of biosimilar of Rituximab CT-P10 in the
treatment of CryoVas [1]. For a better understanding of this
article, an overarching look to the historical picture of Cryo-
Vas and details of the usage of biosimilars will be helpful. | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | Springer | tr_TR |
dc.relation.isversionof | 10.1007/s11739-020-02481-2 | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | Cryoglobulinemic vasculitis | tr_TR |
dc.subject.lcsh | Tıp uygulaması | tr_TR |
dc.title | Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions | tr_TR |
dc.type | info:eu-repo/semantics/article | tr_TR |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Internal and Emergency Medicine | tr_TR |
dc.contributor.department | İç Hastalıkları | tr_TR |
dc.identifier.issue | 16 | tr_TR |
dc.identifier.startpage | 33 | tr_TR |
dc.identifier.endpage | 35 | tr_TR |
dc.description.index | PubMed | tr_TR |
dc.funding | Yok | tr_TR |